Gambro net income falls in 1998:
This article was originally published in Clinica
Swedish company Gambro had net income of Skr2.3 billion ($297 million) in 1998, compared with Skr11.5 billion in 1997. Revenues were Skr18.7 billion, down 4%. In January, the dialysis products and services company announced restructuring plans which are aimed at improving profitability and bringing operating margins to 20% within two years (see Clinica No 843, p 9). Over the past few years, Gambro has divested its non-medical businesses.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.